The US Food and Drug
Administration (FDA) has approved
Cyramza (ramucirumab) for use in
patients with advanced stomach
cancer or gastroesophageal
junction adenocarcinoma.
The treatment was an
angiogenesis inhibitor which
blocked blood supply to tumours,
the FDA said, and was intended for
patients whose cancer could not be
surgically removed or had spread.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Apr 14
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.